NZ599964A - Methods and compositions for treating solid tumors and other malignancies - Google Patents
Methods and compositions for treating solid tumors and other malignanciesInfo
- Publication number
- NZ599964A NZ599964A NZ599964A NZ59996410A NZ599964A NZ 599964 A NZ599964 A NZ 599964A NZ 599964 A NZ599964 A NZ 599964A NZ 59996410 A NZ59996410 A NZ 59996410A NZ 599964 A NZ599964 A NZ 599964A
- Authority
- NZ
- New Zealand
- Prior art keywords
- malignancies
- compositions
- methods
- solid tumors
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26234209P | 2009-11-18 | 2009-11-18 | |
| US29203210P | 2010-01-04 | 2010-01-04 | |
| PCT/US2010/056942 WO2011062939A1 (en) | 2009-11-18 | 2010-11-17 | Methods and compositions for treating solid tumors and other malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599964A true NZ599964A (en) | 2014-08-29 |
Family
ID=43384585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599964A NZ599964A (en) | 2009-11-18 | 2010-11-17 | Methods and compositions for treating solid tumors and other malignancies |
Country Status (17)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781287C (en) | 2009-11-18 | 2018-07-31 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP2014516549A (ja) * | 2011-06-02 | 2014-07-17 | ノバルティス アーゲー | ヘッジホッグ阻害剤療法のためのバイオマーカー |
| WO2013106812A1 (en) * | 2012-01-12 | 2013-07-18 | Board Of Regents, The University Of Texas System | Personalized medicine for the prediction of therapy targeting the hedgehog pathway |
| BR112015010186A2 (pt) * | 2012-11-05 | 2017-07-11 | Nant Holdings Ip Llc | sulfonamida cíclica contendo derivados como inibidores da via de sinalização de hedgehog |
| CN103524535B (zh) * | 2013-10-16 | 2016-07-13 | 苏州云轩医药科技有限公司 | 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物 |
| CA3078769A1 (en) | 2017-10-27 | 2019-05-02 | Boehringer Ingelheim International Gmbh | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors |
| JP2021530463A (ja) * | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| WO2020061584A1 (en) * | 2018-09-21 | 2020-03-26 | Msb Holdings, Inc. | Taste-masked dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| PL1954699T3 (pl) | 2005-11-22 | 2013-01-31 | Kudos Pharm Ltd | Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR |
| UA93548C2 (uk) * | 2006-05-05 | 2011-02-25 | Айерем Елелсі | Сполуки та композиції як модулятори хеджхогівського сигнального шляху |
| SI2057156T1 (sl) | 2006-08-23 | 2017-06-30 | Kudos Pharmaceuticals Limited | Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR |
| UA100684C2 (uk) * | 2007-03-15 | 2013-01-25 | Новартіс Аг | Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog |
| MX2009013273A (es) * | 2007-06-07 | 2010-01-25 | Irm Llc | Derivados de bifenil-carboxamida como moduladores de la senda de hedgehog. |
| US8153633B2 (en) * | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| WO2009112266A1 (en) * | 2008-03-12 | 2009-09-17 | Ludwig-Maximilians-Universität | Active substance combination with gemcitabine for the treatment of epithelial cancer |
| AU2009241561B2 (en) * | 2008-04-29 | 2013-05-16 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
-
2010
- 2010-11-17 US US13/509,857 patent/US20120232087A1/en not_active Abandoned
- 2010-11-17 CA CA2781210A patent/CA2781210A1/en not_active Abandoned
- 2010-11-17 NZ NZ599964A patent/NZ599964A/en not_active IP Right Cessation
- 2010-11-17 RU RU2012125152/15A patent/RU2012125152A/ru unknown
- 2010-11-17 JP JP2012539987A patent/JP2013511526A/ja not_active Ceased
- 2010-11-17 AU AU2010322114A patent/AU2010322114B2/en not_active Ceased
- 2010-11-17 WO PCT/US2010/056942 patent/WO2011062939A1/en active Application Filing
- 2010-11-17 CN CN2010800517592A patent/CN102665700A/zh active Pending
- 2010-11-17 BR BR112012011823A patent/BR112012011823A2/pt not_active IP Right Cessation
- 2010-11-17 CN CN201410410334.6A patent/CN104224791A/zh active Pending
- 2010-11-17 MX MX2012005695A patent/MX2012005695A/es not_active Application Discontinuation
- 2010-11-17 KR KR1020127015545A patent/KR20120107962A/ko not_active Application Discontinuation
- 2010-11-17 EP EP10782767A patent/EP2501370A1/en not_active Withdrawn
-
2012
- 2012-05-07 ZA ZA2012/03325A patent/ZA201203325B/en unknown
- 2012-05-07 IL IL219636A patent/IL219636A0/en unknown
- 2012-05-07 TN TNP2012000205A patent/TN2012000205A1/en unknown
- 2012-05-11 MA MA34856A patent/MA33739B1/fr unknown
- 2012-05-16 CL CL2012001271A patent/CL2012001271A1/es unknown
-
2014
- 2014-10-09 US US14/510,713 patent/US20150025074A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120107962A (ko) | 2012-10-04 |
| EP2501370A1 (en) | 2012-09-26 |
| BR112012011823A2 (pt) | 2019-09-24 |
| RU2012125152A (ru) | 2013-12-27 |
| AU2010322114B2 (en) | 2014-07-31 |
| CN104224791A (zh) | 2014-12-24 |
| US20150025074A1 (en) | 2015-01-22 |
| MX2012005695A (es) | 2012-06-13 |
| AU2010322114A1 (en) | 2012-05-31 |
| ZA201203325B (en) | 2013-01-30 |
| TN2012000205A1 (en) | 2013-12-12 |
| IL219636A0 (en) | 2012-07-31 |
| JP2013511526A (ja) | 2013-04-04 |
| MA33739B1 (fr) | 2012-11-01 |
| CA2781210A1 (en) | 2011-05-26 |
| WO2011062939A1 (en) | 2011-05-26 |
| CL2012001271A1 (es) | 2012-10-12 |
| US20120232087A1 (en) | 2012-09-13 |
| CN102665700A (zh) | 2012-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ599964A (en) | Methods and compositions for treating solid tumors and other malignancies | |
| NZ595572A (en) | Inhibitors of pi3 kinase and / or mtor | |
| TN2019000263A1 (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| HK1139863A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| UA98141C2 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| AU2011274510A8 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
| AU2009215534A8 (en) | Compounds that are ERK inhibitors | |
| MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
| EA201001412A1 (ru) | Ингибиторы киназы pim и способы их применения | |
| MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
| MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
| WO2006113498A3 (en) | 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases | |
| TN2013000237A1 (en) | Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor | |
| WO2012068096A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
| WO2012068106A3 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
| WO2011028044A3 (ko) | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 | |
| WO2011028043A3 (ko) | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 | |
| HK1162502A1 (en) | Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3 | |
| WO2009015368A3 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
| TN2013000392A1 (en) | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor | |
| UA100544C2 (ru) | Гидроксилированный пиримидилциклопентан как ингибитор протеинкиназы акт | |
| UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
| MY165573A (en) | Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof | |
| NZ602807A (en) | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH Effective date: 20140409 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 NOV 2017 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20141210 |
|
| LAPS | Patent lapsed |